Toniolo, Sofia
Cercignani, Mara
Mora-Peris, Borja
Underwood, Jonathan
Alagaratnam, Jasmini
Bozzali, Marco
Boffito, Marta
Nelson, Mark
Winston, Alan
Vera, Jaime H.
Funding for this research was provided by:
Gilead Sciences (NA)
ViiV Healthcare (NA)
Article History
Received: 13 January 2020
Revised: 14 April 2020
Accepted: 12 May 2020
First Online: 4 June 2020
Compliance with ethical standards
: The studies were conducted in accordance with the Declaration of Helsinki, the Uniform Requirements for Manuscripts submitted to Biomedical Journals, were approved by the research ethics committee, the UK regulatory authority and Medicines and Healthcare products Regulatory Agency (MRHA) and were registered with the EudraCT trials database (2014-002284-15) and (2014-003710-84).
: Sofia Toniolo, Mara Cercignani and Borja Mora-Peris report no disclosures. Jonathan Underwood reports travel and honoraria from Gilead Sciences. Jasmini Alagaratnam reports grants to attend conferences from Gilead and MSD. Marco Bozzali reports honoraria and travel support from Lilli, Biogen and Roche. Marta Boffito reports travel and research grants from and has been speaker/advisor for Janssen, Roche, ViiV, Bristol-Myers Squibb, Merck Sharp & Dohme, Gilead, Mylan, Cipla and Teva. Mark Nelson reports grants, personal fees and non-financial support from MSD, ViiV Healthcare, Abbvie, Bristol-Myers Squibb and Gilead Sciences. Alan Winston reports honoraria or research grants from ViiV Healthcare, Gilead Sciences, BMS, Merck and Co. and Janssen. Jaime H Vera reports honoraria and research grants in trials sponsored by Merck, Janssen Cilag, Piramal and Gilead Sciences.